HDAC9 and cancer: VPA, TSA and several other HDAC inhibitors currently undergo clinical trials for treatment of different types of cancer, and two HDAC inhibitors, vorinostat and romidepsin, have been approved by the Food and Drug Administration to treat T-cell lymphoma35, 45.